A Scalable Approach to Assess the Safety of Recently Marketed Systemic Treatments for Atopic Dermatitis in Clinical Practice: First Analysis Cycle of a Sequential Monitoring System
Journal of Investigative Dermatology · 2025
DOI: 10.1016/j.jid.2024.08.034 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Investigative Dermatology, 2025. Verfasst von Maria C Schneeweiss und 11 weiteren Autor:innen. Beteiligte Einrichtung: Dermato-Pharmacoepidemiology Work Group, Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital…. Hauptthemen laut MEDLINE: Dermatitis, Atopic, Janus Kinase Inhibitors, Drug Monitoring. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAMS NIH HHS, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health.
Abstract (Originalsprache)
Targeted systemic immune-modulating drugs to treat atopic dermatitis were highly efficacious in randomized trials. Trials with limited number of subjects leave questions about their safety. We describe a data and analytics structure for the production of timely, high-quality evidence on the comparative safety of recently approved immune-modulating drugs in patients with atopic dermatitis in clinical practice. We established a series of sequential propensity score-balanced cohorts that grow in size with each annual data refresh. Nine health outcomes of interest plus conjunctivitis as a positive tracer outcome were identified. The initial treatment comparison was dupilumab, an IL-4/13 inhibitor, or tralokinumab, an IL-13 inhibitor, versus abrocitinib/upadacitinib, both Jak inhibitors. The first analysis cycle (December 2021-February 2023) compared 269 patients initiating Jak inhibitors and 2650 initiating IL-4/IL-13 inhibitors. Patient characteristics were well-balanced after propensity score matching. Outpatient infections within 180 days occurred in 18% of Jak1 inhibitor initiators versus 12% of dupilumab/tralokinumab initiators (risk ratio = 1.50, 95% confidence interval = 0.96-2.33), whereas acne risks were 7 versus 3%, respectively (risk ratio = 2.29, 95% confidence interval = 0.96-5.46). This sequential monitoring system will produce essential knowledge on the safety of immune-modulating drugs to treat atopic dermatitis on the basis of its growing study size of patients observed in clinical practice.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Dermato-Pharmacoepidemiology Work Group, Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA; Harvard Medical School, Boston, Massachu…
- Dermato-Pharmacoepidemiology Work Group, Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.
- Harvard Medical School, Boston, Massachusetts, USA; Department of Dermatology, Brigham and Women's Hospital, Boston, Massachusetts, USA.
- Department of Dermatology, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
- Department of Dermatology, George Washington University, Washington, District of Columbia, USA.
- Department of Dermatology, Indiana University, Indianapolis, Indiana, USA.
Förderung
- NIAMS NIH HHS
- National Institute of Arthritis and Musculoskeletal and Skin Diseases
- National Institutes of Health
Zitieren
APA
Schneeweiss, M. C., Glynn, R. J., Wyss, R., Anand, P., Jin, Y., Landon, J., Mostaghimi, A., Merola, J. F., Silverberg, J. I., Rosmarin, D. M., Sidbury, R., & Schneeweiss, S. (2025). A Scalable Approach to Assess the Safety of Recently Marketed Systemic Treatments for Atopic Dermatitis in Clinical Practice: First Analysis Cycle of a Sequential Monitoring System. Journal of Investigative Dermatology. https://doi.org/10.1016/j.jid.2024.08.034
Vancouver
Schneeweiss MC, Glynn RJ, Wyss R, Anand P, Jin Y, Landon J, et al. A Scalable Approach to Assess the Safety of Recently Marketed Systemic Treatments for Atopic Dermatitis in Clinical Practice: First Analysis Cycle of a Sequential Monitoring System. Journal of Investigative Dermatology. 2025. doi:10.1016/j.jid.2024.08.034
BibTeX
@article{Schneeweiss2025,
author = {Schneeweiss, Maria C and Glynn, Robert J and Wyss, Richard and Anand, Priyanka and Jin, Yinzhu and Landon, Joan and Mostaghimi, Arash and Merola, Joseph F and Silverberg, Jonathan I and Rosmarin, David M and Sidbury, Robert and Schneeweiss, Sebastian},
title = {A Scalable Approach to Assess the Safety of Recently Marketed Systemic Treatments for Atopic Dermatitis in Clinical Practice: First Analysis Cycle of a Sequential Monitoring System},
journal = {Journal of Investigative Dermatology},
year = {2025},
doi = {10.1016/j.jid.2024.08.034}
}
EUVIMED